EMEA-000128-PIP02-09-M04
Key facts
| Invented name |
Saxenda
|
| Active substance |
liraglutide
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/0309/2021
|
| PIP number |
EMEA-000128-PIP02-09-M04
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of obesity
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Novo Nordisk A/S
Denmark |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|